Granted Patent
B2
US 8,859,562 · App. 10/555,507 · Granted Oct 14, 2014
Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Assignee:
The University of Sheffield
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.
Claims (5)
1. A method of treatment of cancer cells defective in homologous recombination (HR), the method comprising:
identifying a human patient with a familial predisposition to gene-linked hereditary cancer,
wherein said cancer comprises cancer cells defective in homologous recombination;
identifying a compound which inhibits PARP-1, and
administering to said human patient a therapeutically effective amount of said compound.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 20, 2006
From: HELLEDAY, THOMAS
To: THE UNIVERSITY OF SHEFFIELD
Reel/Frame 017968/0155 →
Priority Claims (1)
GB 0317466.1
· Jul 25, 2003
· national
Continuity (1)